Fosdenopterin
Mechanism :
Fosdenopterin is an exogenous source of cyclic pyranopterin monophosphate (cPMP).
This exogenous cPMP is converted to molybdenum cofactor which is needed for some important enzymes (example: sulfite oxidase) to decrease the neurotoxic sulfites.
Indication :
- Molybdenum cofactor deficiency type A.
Dosing :
Available as a lyophilized powder for reconstitution- 9.5 mg (single-dose vial).
Dosage is according to the body weight:
<37 weeks gestational age (preterm neonates)
Initial dose: 0.4 mg/kg/day IV
Month 1: 0.7 mg/kg/day IV
Month 3: 0.9 mg/kg/day IV
>37 weeks gestational age (term neonates)
Initial dose: 0.55 mg/kg/day IV
Month 1: 0.75 mg/kg/day IV
Month 3: 0.9 mg/kg/day IV
>1 year: 0.9 mg/kg/day IV.
Adverse Effect :
Catheter related complications, fever, infections, vomiting, nausea, diarrhea, pain in the abdomen, maculopapular rash, coiugh, sneezing, anemia, eye swelling, agitation, seizures, Gastroenteritis, Otitis media, Viral tonsillitis, Influenza, Pneumonia.
Interaction :
No known major drug interactions.
Lactation :
Limited data available regarding dosage in patients with hepatic impairment.